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effectiveness, we conducted a retrospective lifetime cost-
utility analysis. METHODS: Effectiveness data were
derived from a pivotal placebo-controlled clinical trial,
while utility and cost data were retrieved from published
information. Our pharmacoeconomic model was similar
to that employed in a previous study on lamotrigine (Eur
J Clin Pharmacol 1998;53:421), but used UK cost-of-
illness data. In the ﬁrst analysis, aggregated data on effec-
tiveness were used (clinical endpoint = number of patients
with 50% or more reduction in seizure frequency) allow-
ing a direct comparison between lamotrigine and topira-
mate. Our second analysis was based on individual
patient data from the topiramate trial (clinical endpoint
= individual values of reduction in seizure frequency).
Both analyses were intention-to-treat. RESULTS: The
analysis based on aggregated data showed that topira-
mate (200mg/day) implies an incremental lifetime cost of
£350,326 and a utility of 90 quality-adjusted life-years
(QALYs) for every 100 patients. The same ﬁgures for lam-
otrigine (500mg/day) were £1,324,295 and 58 QALYs,
respectively (discounted values, yearly rate = 3%, year of
costing = 2001). The cost-utility ratio was £3,893 per
QALY gained for adjunctive topiramate as opposed to
£22,833 for lamotrigine, both compared to add-on
placebo. Sensitivity testing suggested a range of £3,129
to £4,870 and of £14,175 to £45,841 for topiramate and
lamotrigine, respectively. Our analysis based on individ-
ual data showed that topiramate compared to placebo
implies an incremental lifetime cost of £1,024,941 and a
utility of 48 QALYs for every 100 patients. The cost
utility ratio is £21,353 per QALY gained. CONCLU-
SIONS: Our results show that, in refractory epilepsy,
adjunctive topiramate has a favourable pharmacoeco-
nomic proﬁle. In this analysis, using aggregated clinical
information generated more optimistic values of cost
effectiveness than using individual patient data.
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OBJECTIVE: To evaluate the clinical utilization of
Dysport and BOTOX for cervical dystonia and ble-
pharospasm. Botulinum toxin (BTX) is safe and effective
therapy for cervical dystonia and blepharospasm. Two
serotype-A toxins, Dysport and BOTOX, are widely pre-
scribed, yet actual clinical utilization is poorly deﬁned or
understood. Previous efforts to compare products have
been limited by sample size or study designs that mandate
drug usage according to protocol. Utilization in actual
clinical practice is more appropriate to determine the true
effective dose and dose ratios. METHODS: Two sites
where BTX is prescribed for cervical dystonia and ble-
pharospasm were identiﬁed in the UK (Bristol and Hull)
as part of a retrospective observational study. Each 
site culled BTX data from medical records of patients
who received Dysport before switching to BOTOX.
RESULTS: Assessment of 29 patients (14 cervical dysto-
nia, 15 blepharospasm) provided a total of 456 injections
for computation of mean dose, which was 839.6 ± 308.5
units (Dysport) versus 162.8 ± 64.9 units (BOTOX) for
cervical dystonia; and 109.9 ± 33.9 units (Dysport) versus
23.5 ± 8.0 units (BOTOX) for blepharospasm. The ratios
of mean dose ranged from 2 :1 (Dysport to BOTOX
units) to 9 :1 (Dysport to BOTOX units), with over 
79% of patients utilizing a ratio >4:1. When current
pricing for Dysport (£164.74/500 units) and BOTOX
(£128.93/100 units) is applied, incremental costs of
£66.68/patient and £5.90/patient were incurred with
Dysport for cervical dystonia and blepharospasm respec-
tively. CONCLUSION: Results demonstrate that no one
ratio exists between Dysport and BOTOX, consistent
with the UK labeling: units of different serotype-A toxins
are not interchangeable and comparisons based on simple
dosage conversion factors are not applicable. Current
pricing suggests incremental cost savings with BOTOX,
other outcomes, including adverse events, also should 
be considered to better understand the overall costs and
consequences of treatment.
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OBJECTIVE: To examine the impact of glatiramer
acetate (GA) versus beta interferons 1a (1A) and 1b (1B)
on relapse rates as well as utilization and costs among
patients with multiple sclerosis (MS) in a managed care
setting. METHODS: Data were obtained from a national
retrospective database of patient-linked medical and
pharmacy claims from January 1996 to June 2001.
Patients were followed from the ﬁrst prescription for
immunomodulatory therapy until plan disenrollment or
end of study timeframe. The incidence of all relapses
(deﬁned as hospitalization for MS or ambulatory visit fol-
lowed by use of systemic corticosteroids) as well as uti-
lization and costs of MS-related care were examined for
each group. Data were adjusted for variable follow-up
using survival techniques; the risk of relapse was evalu-
ated using a Cox proportional hazards model. RESULTS:
A total of 8,457 patients receiving immunomodulatory
therapy were included in the study cohort (1,674, 5,031,
and 1,752 for GA, 1A, and 1B respectively); follow-up
averaged 17.3 months. Three-quarters of patients were
female; the mean age was 42.2 years. The risk of relapse
at one year post-therapy initiation was signiﬁcantly
increased for the beta interferons relative to GA (hazard
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rates: 1.15 and 1.51 for 1A and 1B respectively, p < 0.01).
Mean (SD) costs of care at one year of follow-up also
were reduced among GA patients ($9,522 [$9,706] vs.
$9,957 [$9,083] and $10,185 [$9,526] for 1A and 1B
respectively). Findings persisted in multivariate analyses
controlling for differences in demographic characteristics
and propensity scores for immunomodulatory therapy.
CONCLUSIONS: Glatiramer acetate is associated with
reductions in the incidence of relapse and costs of care
relative to the beta interferons among this large group of
managed-care patients with MS.
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The Total Outcome of Pain Scale, TOPS, is a fully vali-
dated disease-speciﬁc outcome measurement tool for use
in patients with chronic pain. The TOPS provides much
greater sensitivity and speciﬁcity for measuring outcomes.
The 60°V-item TOPS questionnaire contains the SF-36
and information on Pain Symptom, Functional 
Limitations, Perceived Family/Social Disability, Real
Family/Social Disability and Formal Work Disability.
Unlike the SF-36, TOPS is precise enough to monitor
outcome over time in individual patients. All patients at
the University of Utah Pain Management Center complete
TOPS at evaluation, three months, six months, and then
every six months for the duration of therapy. Paper forms
are scanned into an Access database. This produces a
report that summarizes current and prior TOPS scores for
the patient and which is put into the patient’s medical
record. From July 1, 1997 through August 2, 2001, 3454
TOPS instruments were completed and entered. This rep-
resented 2692 individual patients. Most (80.5%) of
patients completed one TOPS; the remainder had 2 or
more. This population was 62.2% female and had the fol-
lowing characteristics (median values): age (40–44), years
of education (13), income $30,000–$39,999. The 6 most
common diagnoses and ICD 9 codes were: myalgia and
myositis, unspeciﬁed (729.11, low back pain, low back
syndrome (724.2), pain in limb (729.5), neuralgia, neuri-
tis, and radiculitis, unspeciﬁed (729.2), cervicalgia, pain
in neck (723.1) and headache (784.0). Mean responses
were as follows: ICD 9 Code PCS MCS Pain Symptom
Score Work Disability 729.1 28.9 39.7 72.2 37.7 724.2
27.1 40.1 72.9 47.4 729.5 27.9 40.4 75.3 38.7 729.2
28.9 40.1 73.0 46.8 723.1 30.5 37.6 73.2 40.1 784.0
31.6 37.6 71.2 31.8. Data collection is ongoing, with
20–30 surveys completed weekly. By the end of 2002,
data on approximately 5000 TOPS administrations will
be available and will be included in the presentation.
Querying the database may provide valuable data on rel-
ative outcomes by intervention and clinician.
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OBJECTIVES: To determine rate of adoption of saliva
concentrations as a monitoring method for antiepileptic
drugs (AEDs). To determine whether child neurologists
would prefer saliva testing to serum testing to obtain 
AED concentrations for clinical practice. METHODS:
A survey asked participants about use, availability, and
value to the physician of saliva AED concentrations.
Respondents chose between the following four responses
when considering value: 1) Very valuable, willing to
spend 1/2 hour of time per patient to arrange; 2) Moder-
ately valuable, willing to spend 10 minutes of time per
patient to arrange; 3) Not very valuable, might use test
but would not spend extra time to arrange; and 4) Of no
special value, I doubt that I would use such a test. All
members of the Child Neurology Society were surveyed.
Surveys were re-mailed to non-responders after one- and
two-month intervals. RESULTS: We mailed 1006 surveys
and received 546 responses (54%) and 57 surveys were
returned undelivered. Less than 1% of respondents had
obtained a saliva AED concentration in the last year.
Seven percent stated there was an available laboratory to
perform saliva AED concentration determinations. Fifty-
three percent of individuals indicated that having a pain-
free method of AED concentration determination was
very or moderately valuable to them and 68% stated that
the ability to obtain real-time samples outside of the clin-
ical environment was very or moderately valuable. CON-
CLUSIONS: Most child neurologists have not obtained
saliva AED concentrations and perceive they do not have
this technology available to them. The majority of respon-
dents would be willing to spend 10–30 minutes of time
to arrange for saliva AED concentrations to prevent
patient discomfort and obtain real-time concentrations.
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OBJECTIVES: The growing attention to the social aspect
of epilepsy and the necessity to improve the system of 
care require knowledge of QOL and pharmacoeconomic
